Outlook on the World Market for Anemia & Other Blood Disorder Drugs, 2020-2030 - ResearchAndMarkets.com

DUBLIN--()--The "Anemia And Other Blood Disorder Drugs Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering.

The global anemia and other blood disorder drugs market was valued at about $19.7 billion in 2018 and is expected to grow to $29.37 billion at a CAGR of 10.5% through 2022. Major players in the market are Amgen, GlaxoSmithKline, Akebia therapeutics, Bayer and Pfizer.

North America was the largest region in the anemia and other blood disorder drugs market in 2018. The anemia and other blood disorder drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

Companies Profiled: Amgen, GlaxoSmithKline, Akebia Therapeutics, Bayer and Pfizer.

The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, in the year 2017, anemia was found to be most frequent disease in elderly population (> 65 years of age), reaching a prevalence rate of around 17%. In 2014, the World Bank reported that anemia is the 8th leading cause of disease among the women and young population. Growth in prevalence rate of anemia drives the market.

There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids or a combination of these substances or might be derived from living organisms like humans, animals or microorganisms or that may contain components of living organisms. The growth in use of biologics over the drugs restricts the market resulting in decline of amount of drugs being used for the treatment of anemia & other blood disorders. For example, in 2015 Hospira, a medical device and pharmaceutical company submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, on May 2018, FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. The increase in use of biologics will hamper the growth of the market.

Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology and cost. Such collaborations are also helpful to the companies in case of expiring licenses and stringent regulatory environment. For example, in 2017, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. entered into an agreement to manufacture and commercialize Vadadustat, an oral HIF stabilizer, used for the treatment of anemia. Another such example is, Cipla collaborating with Hetero Drugs for developing a biosimilar for anemia drug in the year 2014.

The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get their drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark.

In 2019, AMAG Pharmaceutical, an American pharmaceutical company agreed to acquire Perosphere for $415 million. The acquisition would result in expanding AMAG's pipeline and enhance its presence in Hematology drugs market with the help of Perosphere's next-generation Anticoagulant reversal agent called Ciraparantag. Perosphere is a specialty pharmaceutical company focusing on rescue drug medications. The Company was established in 2011 and is headquartered in Danbury, Connecticut, USA.

Key Topics Covered

1. Executive Summary

2. Anemia And Other Blood Disorder Drugs Market Characteristics

3. Anemia And Other Blood Disorder Drugs Market Size And Growth

3.1. Global Anemia And Other Blood Disorder Drugs Historic Market, 2015 - 2019, $ Billion

3.1.1. Drivers Of The Market

3.1.2. Restraints On The Market

3.2. Global Anemia And Other Blood Disorder Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion

3.2.1. Drivers Of The Market

3.2.2. Restraints On the Market

4. Anemia And Other Blood Disorder Drugs Market Segmentation

4.1. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Iron Deficiency Anemia
  • Chronic Kidney Disease Anemia
  • Sickle Cell Anemia
  • Aplastic Anemia

4.2. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Hospitals Pharmacy
  • Online Pharmacy
  • Pharmacy

4.3. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Oral
  • Injectable

4.4. Global Anemia And Other Blood Disorder Drugs Market, Segmentation By Anemia Type , Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

  • Microcytic (Low MCV)
  • Normocytic (Normal MCV)
  • Macrocytic (High MCV)

5. Anemia And Other Blood Disorder Drugs Market Regional And Country Analysis

5.1. Global Anemia And Other Blood Disorder Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

5.2. Global Anemia And Other Blood Disorder Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

Companies Mentioned (A-Z)

  • Abbott Laboratories
  • ACIST Medical Systems Inc.
  • Akebia Therapeutics
  • Amgen
  • B. Braun Melsungen AG
  • Bayer
  • Biosensors International Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Cordis Corporation
  • GE Healthcare
  • GlaxoSmithKline
  • Johnson & Johnson
  • Medtronic Inc.
  • Novacam Technologies Inc.
  • Pfizer
  • Terumo Corporation

For more information about this report visit https://www.researchandmarkets.com/r/g8gkyt

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900